PureTech Health Plc Ret. on equity
What is the Ret. on equity of PureTech Health Plc?
The Ret. on equity of PureTech Health Plc is -21.58%
What is the definition of Ret. on equity?
Return on equity is a measure of the profitability of a business in relation to the book value of the shareholder equity. It is computed by dividing fiscal year net income by total shareholder equity.
ttm (trailing twelve months)
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
Ret. on equity of companies in the Health Care sector on LSE compared to PureTech Health Plc
What does PureTech Health Plc do?
PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and dementia-related psychosis; a hydrogel platform technology to treat obesity and other chronic metabolic diseases; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; a immunomodulation platform to treat chronic and acute inflammatory disorders; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a digital treatments to treat cognitive dysfunction associated with neurology and psychiatry conditions. It also provides hematopoietic stem cell based therapies to treat hematological malignancies; a voice-based technology platform to measure health when a person speaks; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100, an oral small molecule drug candidate to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210, a IgG1 monoclonal antibody; Glyph, a synthetic lymphatic targeting chemistry platform; milk exosome-based technology to enable the oral administration of macromolecule therapeutic payloads; and meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Roche Holding AG; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Companies with ret. on equity similar to PureTech Health Plc
- Harvest Gold has Ret. on equity of -21.61%
- Aura Resources has Ret. on equity of -21.61%
- First Light Capital Corp has Ret. on equity of -21.59%
- Great Southern Mining has Ret. on equity of -21.59%
- Rambler Metals and Mining PLC has Ret. on equity of -21.58%
- Rambler Metals and Mining PLC has Ret. on equity of -21.58%
- PureTech Health Plc has Ret. on equity of -21.58%
- KEFI Minerals Plc has Ret. on equity of -21.58%
- International Business Settlement has Ret. on equity of -21.56%
- Leading Edge Materials has Ret. on equity of -21.53%
- Leading Edge Materials has Ret. on equity of -21.53%
- Quantum Graphite has Ret. on equity of -21.51%
- Magnis Technologies has Ret. on equity of -21.50%